CALLIDITAS THERAPEUTICS AB SER'B'NPV revenue breakdown overview

CALLIDITAS THERAPEUTICS AB SER'B'NPV revenue for the last year amounted to 1.21 B SEK, the most of which — 1.09 B SEK — came from its highest performing source at the moment, Therapeutics for Renal Disease Immunoglobulin, the year earlier bringing 375.51 M SEK. The greatest contribution to the revenue figure was made by United States — last year it brought CALLIDITAS THERAPEUTICS AB SER'B'NPV 1.08 B SEK, and the year before that — 372.25 M SEK.